Heart valve drug aims to stop stroke and kidney failure in one shot
NCT ID NCT05145283
First seen Apr 24, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tested a drug called conestat alfa to see if it could prevent strokes and kidney injuries in people undergoing a minimally invasive heart valve replacement (TAVI). 141 patients with severe aortic stenosis received either the drug or a placebo before their procedure. The goal was to see if the drug reduced brain lesions and kidney damage seen on MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stadtspital Triemli Zürich, Division of Cardiology
Zurich, 8063, Switzerland
-
University Hospital Basel, Division of Internal Medicine
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.